FORGE Life Science CEO Lillian Chiang was former VP of Translational Medicine at Kadmon Corporation. She was responsible for strategy and translation from early discovery through proof of concept in man. Previously, she built from scratch, state-of-the-art technologies, drug discovery & development teams, and businesses at Millennium Pharmaceuticals, Purdue Pharma, and Aestus Therapeutics. Her array technology platform was central in Millennium's $218 and $465M collaborations with Monsanto and Bayer, respectively. At Purdue she staffed and directed the Molecular Biology department from scratch. At Aestus, she applied her own data mining algorithms to identify drug-repositioning assets to acquire and develop in a virtual pharma environment. Aestus' first in-licensed product from Astellas was successfully advanced from novel mechanism of action & therapeutic hypothesis to completion of phase 2A trial in 5 years and $5M spend. BS, MIT; PhD, U. Wisconsin; Post-Doc, Stanford; MBA, Wharton.